STOCK TITAN

Liminal Biosciences Inc - LMNL STOCK NEWS

Welcome to our dedicated news page for Liminal Biosciences (Ticker: LMNL), a resource for investors and traders seeking the latest updates and insights on Liminal Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Liminal Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Liminal Biosciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.81%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.96%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.86%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.86%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.83%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
conferences earnings
Liminal Biosciences Inc

Nasdaq:LMNL

LMNL Rankings

LMNL Stock Data

27.62M
1.26M
61.26%
0.77%
0.02%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Canada
Laval

About LMNL

liminal biosciences inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. it operates through two segments, small molecule therapeutics and plasma derived therapeutics. the small molecule therapeutics segment's lead product candidate is fezagepras (pbi-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and alstrã¶m syndrome. the plasma derived therapeutics segment provides plasma protein purification system, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. it also engages in developing ryplazim for the treatment of congenital plasminogen deficiency. the company operates in canada, the united kingdom, and the united states. the company was formerly known as prometic life sciences inc. and changed its name to liminal biosciences inc. in october